MCID: OLG002
MIFTS: 66

Oligodendroglioma

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Oligodendroglioma

MalaCards integrated aliases for Oligodendroglioma:

Name: Oligodendroglioma 11 19 58 28 53 5 43 14 16 71 75
Oligodendroglial Neoplasm 11 71
Oligodendroglial Tumor 11 58
Well Differentiated Oligodendroglioma 71
Oligodendroglial Tumors 53

Characteristics:


Inheritance:

Oligodendroglial Tumor: Multigenic/multifactorial 58

Prevelance:

Oligodendroglioma: 1-9/1000000 (Europe) 58
Oligodendroglial Tumor: 1-9/1000000 (Europe, United States) 58

Age Of Onset:

Oligodendroglioma: All ages 58
Oligodendroglial Tumor: Adult 58

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 11 DOID:3181
MeSH 43 D009837
NCIt 49 C3288
SNOMED-CT 68 443936004
ICD10 via Orphanet 32 C71.9
UMLS via Orphanet 72 C0028945
UMLS 71 C0028945 C0751396 C1335110

Summaries for Oligodendroglioma

GARD: 19 Oligodendrogliomas are brain tumors arising from oligodendrocytes, a type of cell that makes up the supportive (glial) tissue of the brain. They can be low-grade (grade II) or high-grade (grade III, also called anaplastic). While they can be found anywhere within the cerebral hemisphere, they are most common in the frontal and temporal lobes. They are generally soft, grayish-pink tumors that often contain mineral deposits (calcifications), areas of hemorrhage, and/or cysts. Common symptoms include seizures, headaches and changes in personality. Other symptoms vary by the size and location of the tumor. The exact cause of opigodendrogliomas is unknown. Some appear to have a chromosome abnormality involving loss of chromosomes 1p and 19q.

MalaCards based summary: Oligodendroglioma, also known as oligodendroglial neoplasm, is related to oligoastrocytoma and anaplastic oligodendroglioma, idh-mutant and 1p/19q-codeleted. An important gene associated with Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2), and among its related pathways/superpathways are Prolactin Signaling and Cellular Senescence. The drugs Dabrafenib and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and spinal cord, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Decreased viability in pancreas lineage

Orphanet 58 Oligodendroglioma: A rare glial tumor characterized by a highly cellular lesion that is diffusly infiltrating at the periphery and consists of evenly-spaced monomorphic cells with the oligodendroglial phenotype. It typically occurs in the supratentorial white matter. Histologically, the cells are uniformly round to oval with round nuclei, delicate chromatin and small nucleoli. Most patients present with seizures.

Oligodendroglial tumor: Oligodendrogliomas are cerebral tumors that are differentiated from other gliomas on the basis of their unique genetic characteristics and better response to chemotherapy. These tumors are classified according to their grade (low grade oligodendrogliomas: grade II of the WHO classification and anaplastic oligodendrogliomas: grade III of the WHO classification) and according to their pure or mixed histology (oligoastrocytomas).

Wikipedia: 75 Oligodendrogliomas are a type of glioma that are believed to originate from the oligodendrocytes of the... more...

Related Diseases for Oligodendroglioma

Diseases in the Oligodendroglioma family:

Adult Oligodendroglioma

Diseases related to Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 546)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 32.9 MGMT IDH2 GFAP
2 anaplastic oligodendroglioma, idh-mutant and 1p/19q-codeleted 32.8 IDH2 IDH1
3 adult oligodendroglioma 32.7 OLIG2 IDH2 IDH1 FUBP1
4 glioma susceptibility 1 32.7 TP53 IDH2 IDH1
5 childhood oligodendroglioma 32.6 OLIG2 MGMT IDH2 IDH1 FUBP1
6 spinal cord oligodendroglioma 32.5 TP53 SYP MGMT IDH1 GFAP EGFR
7 anaplastic oligodendroglioma 32.1 TP53 PTEN POT1 OLIG2 OLIG1 MGMT
8 mixed oligodendroglioma-astrocytoma 32.1 TP53 PTEN MGMT IDH2 IDH1 CDKN2B
9 mixed glioma 31.9 TP53 PTEN OLIG2 MGMT IDH2 IDH1
10 central neurocytoma 31.2 SYP OLIG2 IDH1 GFAP
11 dysembryoplastic neuroepithelial tumor 31.1 SYP OLIG2 IDH2 IDH1 GFAP
12 cellular ependymoma 31.1 TP73 SYP MGMT GFAP EGFR
13 glioma 31.1 TP53 PTEN MGMT IDH2 IDH1 EGFR
14 clear cell ependymoma 31.0 SYP OLIG2 GFAP
15 high grade glioma 30.9 TP53 PTEN MGMT GFAP EGFR CDKN2B
16 brain cancer 30.9 TP53 SYP PTEN OLIG2 OLIG1 MGMT
17 ganglioglioma 30.9 TP53 SYP GFAP BRAF
18 hydrocephalus 30.9 TP53 SYP PTEN MBP GFAP
19 glioblastoma 30.9 TP53 PTEN OLIG2 MGMT IDH2 IDH1
20 central nervous system cancer 30.9 TP53 MGMT IDH1 EGFR
21 teratoma 30.9 TP53 SYP PTEN GFAP CDKN2A
22 low grade glioma 30.9 TP53 SYP PTEN OLIG2 MGMT IDH2
23 gangliocytoma 30.8 SYP PTEN IDH1 GFAP
24 neurilemmoma 30.7 SYP MBP GFAP
25 astroblastoma 30.6 OLIG2 IDH1 GFAP
26 neurofibromatosis 30.6 TP53 PTEN EGFR CDKN2A BRAF
27 pilocytic astrocytoma 30.6 TP73 TP53 SYP PTEN OLIG2 MGMT
28 diffuse astrocytoma 30.5 TP53 PTEN OLIG2 MGMT IDH2 IDH1
29 malignant astrocytoma 30.5 TP53 PTEN MGMT IDH1 EGFR
30 toxic encephalopathy 30.5 TP53 SYP GFAP
31 meningioma, familial 30.5 TP73 TP53 SYP PTEN OLIG2 MGMT
32 alpha-thalassemia 30.5 TP53 MGMT IDH2 IDH1
33 pilocytic astrocytoma of cerebellum 30.4 IDH1 BRAF
34 brain glioma 30.4 TP53 PTEN OLIG2 MGMT IDH2 IDH1
35 diffuse midline glioma, h3 k27m-mutant 30.4 TP53 OLIG2 MGMT IDH1
36 pleomorphic xanthoastrocytoma 30.4 TP53 SYP MGMT IDH2 IDH1 CDKN2A
37 malignant teratoma 30.4 TP53 SYP GFAP
38 fibrillary astrocytoma 30.4 TP53 IDH2 IDH1 GFAP
39 lynch syndrome 30.4 TP53 PTEN MGMT IDH1 EGFR CDKN2A
40 enchondroma 30.4 IDH2 IDH1
41 obstructive hydrocephalus 30.4 SYP OLIG2 GFAP
42 high grade ependymoma 30.4 OLIG2 MGMT IDH1 GFAP
43 cerebral neuroblastoma 30.4 SYP GFAP
44 mixed cell type cancer 30.3 TP53 SYP PTEN EGFR CDKN2A
45 medulloblastoma 30.3 TP73 TP53 SYP PTEN OLIG2 MGMT
46 cerebral lymphoma 30.3 MGMT IDH1
47 pilomyxoid astrocytoma 30.3 SYP OLIG2 MGMT IDH2 IDH1 CDKN2A
48 anaplastic astrocytoma 30.3 TP73 TP53 PTEN OLIG2 OLIG1 MGMT
49 neuroblastoma 30.2 TP73 TP53 SYP PTEN GFAP EGFR
50 adult astrocytic tumor 30.2 TP53 PTEN IDH2 IDH1

Graphical network of the top 20 diseases related to Oligodendroglioma:



Diseases related to Oligodendroglioma

Symptoms & Phenotypes for Oligodendroglioma

GenomeRNAi Phenotypes related to Oligodendroglioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.2 CDKN2A CIC GMNN POT1 PTEN TP73
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.2 BRAF CDKN2A CIC GMNN POT1 PTEN
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 10.2 CIC POT1 TP53 TP73
4 no effect GR00402-S-1 10.15 BRAF CDKN2A CDKN2B CDKN2C CIC EGFR
5 no effect GR00402-S-2 10.15 BRAF CDKN2A CDKN2B CDKN2C CIC EGFR
6 Decreased viability in pancreas lineage GR00235-A 9.16 IDH1 TP53

MGI Mouse Phenotypes related to Oligodendroglioma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.48 BRAF CDKN2A CDKN2C CIC EGFR FUBP1
2 growth/size/body region MP:0005378 10.4 BRAF CDKN2A CDKN2C CIC EGFR FUBP1
3 homeostasis/metabolism MP:0005376 10.38 BRAF CDKN2A CDKN2B CDKN2C EGFR GFAP
4 cellular MP:0005384 10.33 BRAF CDKN2A CDKN2B CDKN2C EGFR GFAP
5 neoplasm MP:0002006 10.32 BRAF CDKN2A CDKN2B CDKN2C EGFR IDH2
6 endocrine/exocrine gland MP:0005379 10.29 BRAF CDKN2A CDKN2B CDKN2C EGFR FUBP1
7 behavior/neurological MP:0005386 10.28 BRAF CDKN2A CDKN2C CIC FUBP1 GFAP
8 immune system MP:0005387 10.28 BRAF CDKN2A CDKN2B CDKN2C EGFR FUBP1
9 normal MP:0002873 10.22 BRAF EGFR GFAP GMNN MBP POT1
10 embryo MP:0005380 10.15 BRAF CDKN2A EGFR FUBP1 GMNN POT1
11 respiratory system MP:0005388 10.15 BRAF CDKN2A CDKN2C CIC EGFR FUBP1
12 no phenotypic analysis MP:0003012 10.1 CDKN2A CDKN2B EGFR MGMT OLIG2 POT1
13 digestive/alimentary MP:0005381 10.08 BRAF CDKN2A EGFR GFAP POT1 PTEN
14 pigmentation MP:0001186 10.06 BRAF CDKN2A EGFR POT1 PTEN TP53
15 reproductive system MP:0005389 10.06 BRAF CDKN2A CDKN2B CDKN2C EGFR GMNN
16 hematopoietic system MP:0005397 10 BRAF CDKN2A CDKN2B CDKN2C EGFR FUBP1
17 vision/eye MP:0005391 9.96 BRAF CDKN2A EGFR GFAP GMNN MBP
18 mortality/aging MP:0010768 9.91 BRAF CDKN2A CDKN2B CDKN2C CIC EGFR
19 integument MP:0010771 9.32 BRAF CDKN2A CDKN2B CDKN2C EGFR FUBP1

Drugs & Therapeutics for Oligodendroglioma

Drugs for Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760
2
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
3
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
4
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
5 Antimitotic Agents Phase 3
6 Tubulin Modulators Phase 3
7
Lapatinib Approved, Investigational Phase 1, Phase 2 231277-92-2, 388082-78-8 208908
8
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
9
Erlotinib Approved, Investigational Phase 1, Phase 2 183319-69-9, 183321-74-6 176870
10
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
11
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
12
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
13
Picropodophyllin Approved, Investigational Phase 1, Phase 2 518-28-5, 477-47-4 10607 72435
14
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
15
Sorbitol Approved, Investigational Phase 1, Phase 2 69-65-8, 50-70-4 453 6251 5780
16
Lenograstim Approved, Investigational Phase 2 135968-09-1
17
Carbamide peroxide Approved Phase 2 124-43-6
18
Aflibercept Approved Phase 2 862111-32-8 124490314
19
Carmustine Approved, Investigational Phase 2 154-93-8 2578
20
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
21
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
22
Sargramostim Approved, Investigational Phase 2 123774-72-1
23
Aldesleukin Approved Phase 2 110942-02-4
24
Mercaptopurine Approved Phase 2 50-44-2 667490
25
Streptozocin Approved, Investigational Phase 2 18883-66-4, 66395-18-4 29327
26
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
27
Plerixafor Approved Phase 1, Phase 2 110078-46-1 65015
28
Etoposide Approved Phase 2 33419-42-0 36462
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
31
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
32
Busulfan Approved, Investigational Phase 2 55-98-1 2478
33
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
34
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3 135329020
35
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
36
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
37
Cetuximab Approved Phase 1, Phase 2 205923-56-4
38
Lopinavir Approved Phase 2 192725-17-0 92727
39
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
40
D-Phenylalanine Approved, Experimental, Investigational, Nutraceutical Phase 1, Phase 2 63-91-2, 673-06-3 6140 71567
41
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
42
Isotretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4, 4759-48-2 5538 444795 5282379
43
Trebananib Investigational Phase 2 894356-79-7
44
Tipifarnib Investigational Phase 2 192185-72-1 159324
45
Molgramostim Investigational Phase 2 99283-10-0
46
Etirinotecan pegol Investigational Phase 2 848779-32-8 71300725
47
Imetelstat Investigational Phase 2 868169-64-6
48 Fluorides Phase 2
49 Radiopharmaceuticals Phase 2
50 Antidotes Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 192)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
2 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
3 PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
4 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
5 Phase III Intergroup Randomized Comparison of Radiation Alone vs. Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
6 A Randomized Trial of Delayed Radiotherapy in Patients 1p/19q Codeleted Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery Recruiting NCT04702581 Phase 3 PCV chemotherapy;Radiotherapy and PCV chemotherapy
7 Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial Recruiting NCT05331521 Phase 3 CETEG;PCV
8 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
9 A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial. Active, not recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
10 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3 Temozolomide
11 A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Withdrawn NCT04105374 Phase 2, Phase 3 Extended Release Flucytosine;Temozolomide
12 A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
13 A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas Unknown status NCT02209428 Phase 2 Temozolomide
14 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
15 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
16 Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors Completed NCT00042991 Phase 1, Phase 2 gefitinib
17 Phase I/II Trial of Imatinib Mesylate; (Gleevec; STI571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00049127 Phase 1, Phase 2 Imatinib Mesylate
18 Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas Completed NCT01051557 Phase 1, Phase 2 Perifosine;Temsirolimus
19 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Pure and Mixed Anaplastic Oligodendroglioma Completed NCT00400816 Phase 2 temozolomide
20 The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
21 A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma Completed NCT00003372 Phase 2 topotecan hydrochloride
22 Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Completed NCT02530320 Phase 2 Palbociclib
23 Phase II Trial of Continuous Dose Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
24 Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma or Oligoastrocytoma Completed NCT00303849 Phase 1, Phase 2 Carboplatin;Etoposide;Etoposide Phosphate;Mannitol;Melphalan;Sodium Thiosulfate
25 Phase II Treatment of Adults With Newly Diagnosed, Progressive or Recurrent Primary Malignant Anaplastic Oligodendroglioma With Temodal Completed NCT00003465 Phase 2 temozolomide
26 A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
27 Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma Completed NCT00679354 Phase 2 cilengitide
28 Primary Chemotherapy by BCNU-TMZ Combination in Newly Diagnosed Anaplastic Oligodendrocytic Tumors: Phase II Trial With Translational Molecular Analysis Completed NCT04755023 Phase 2 Bis-Chloroethyl-Nitroso-Urea (BCNU) withTemozolomide
29 The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma Completed NCT00392171 Phase 2 Temozolomide
30 A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) Completed NCT00823797 Phase 2 Bendamustine Hydrochloride
31 A Phase 2 Trial of Tandutinib in Combination With Bevacizumab for Patients With Recurrent High-Grade Gliomas Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
32 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2 Everolimus
33 A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Completed NCT00499473 Phase 2 sunitinib malate
34 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
35 Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas Completed NCT00369590 Phase 2
36 A Phase I-II Trial of Depsipeptide in Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
37 Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma Completed NCT01609790 Phase 2
38 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
39 A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma Completed NCT00070525 Phase 2 tipifarnib
40 A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma Completed NCT01635283 Phase 2
41 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
42 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
43 Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
44 Efficacy of a Protracted Temozolomide Schedule in Patients With Progression After Standard Dose Temozolomide for High-grade Gliomas Completed NCT00575887 Phase 2 Temozolomide
45 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
46 Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients With Recurrent Glioblastoma Multiforme Completed NCT01648348 Phase 1, Phase 2
47 A Phase II Study of Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2 Temozolomide
48 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
49 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
50 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate

Search NIH Clinical Center for Oligodendroglioma

Cochrane evidence based reviews: oligodendroglioma

Genetic Tests for Oligodendroglioma

Genetic tests related to Oligodendroglioma:

# Genetic test Affiliating Genes
1 Oligodendroglioma 28

Anatomical Context for Oligodendroglioma

Organs/tissues related to Oligodendroglioma:

MalaCards : Brain, Eye, Spinal Cord, Breast, Endothelial, Temporal Lobe, Bone Marrow

Publications for Oligodendroglioma

Articles related to Oligodendroglioma:

(show top 50) (show all 3379)
# Title Authors PMID Year
1
Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. 53 62
19967449 2010
2
Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. 53 62
20150384 2010
3
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. 53 62
19901104 2009
4
Genetic alterations and signaling pathways in the evolution of gliomas. 53 62
19737147 2009
5
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. 53 62
19554337 2009
6
Cyclooxygenase-2 expression in astrocytes and microglia in human oligodendroglioma and astrocytoma. 53 62
20052522 2009
7
Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. 53 62
19934553 2009
8
[Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma]. 53 62
19781190 2009
9
[Common mechanism underlying oligodendrocyte development and oligodendrogliomagenesis]. 53 62
19618851 2009
10
Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. 53 62
19357963 2009
11
Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization. 53 62
19391220 2009
12
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 53 62
19346643 2009
13
p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. 53 62
19240607 2009
14
[Expression of myelin basic protein and glial fibrillary acidic protein genes in human glial brain tumors]. 53 62
19663312 2009
15
Molecular neuropathology of gliomas. 53 62
19333441 2009
16
Oligodendrogliomas in relation to astrocytes differentiation. Clinicopathologic and immunohistochemical study. 53 62
18774492 2008
17
Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction. 53 62
18575733 2008
18
[Radiotherapy of adult glial tumors: new developments and perspectives]. 53 62
18565351 2008
19
Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. 53 62
18552083 2008
20
Predictive and prognostic markers in neuro-oncology. 53 62
18090916 2007
21
RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. 53 62
17588166 2007
22
Receptor-targeted quantum dots: fluorescent probes for brain tumor diagnosis. 53 62
17867825 2007
23
Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. 53 62
17435181 2007
24
Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. 53 62
17390041 2007
25
Clinical significance of ABCA2' a possible molecular marker for oligodendrogliomas. 53 62
17415208 2007
26
Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. 53 62
17319279 2007
27
Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. 53 62
17146289 2006
28
Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. 53 62
16874663 2006
29
Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. 53 62
16598485 2006
30
Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival. 53 62
16292483 2006
31
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. 53 62
16541434 2006
32
Survival analysis of presumptive prognostic markers among oligodendrogliomas. 53 62
16116609 2005
33
OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1. 53 62
16103065 2005
34
Ceramide regulation of the tumor suppressor phosphatase PTEN in rafts isolated from neurotumor cell lines. 53 62
15968641 2005
35
Correlation of glial fibrillary acidic protein (GFAP) with grading of the neuroglial tumours. 53 62
16202357 2005
36
Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. 53 62
15834925 2005
37
Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. 53 62
15899783 2005
38
Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression. 53 62
16038527 2005
39
Mutational study of the 1p located genes p18ink4c, Patched-2, RIZ1 and KIF1B in oligodendrogliomas. 53 62
15711769 2005
40
Mutation analysis of B-RAF gene in human gliomas. 53 62
15791479 2005
41
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. 53 62
15455350 2005
42
Gene expression profiling and subgroup identification of oligodendrogliomas. 53 62
15208679 2004
43
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. 53 62
15118874 2004
44
p53 protein alterations in adult astrocytic tumors and oligodendrogliomas. 53 62
15269478 2004
45
Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors. 53 62
15164981 2004
46
Anti-human Olig2 antibody as a useful immunohistochemical marker of normal oligodendrocytes and gliomas. 53 62
15111318 2004
47
Acid sphingomyelinase and inhibition by phosphate ion: role of inhibition by phosphatidyl-myo-inositol 3,4,5-triphosphate in oligodendrocyte cell signaling. 53 62
15086520 2004
48
Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. 53 62
14730454 2004
49
Transcriptional regulation of the human UDP-galactose:ceramide galactosyltransferase (hCGT) gene expression: functional role of GC-box and CRE. 53 62
15229398 2004
50
Heterogeneity in the expression of markers for drug resistance in brain tumors. 53 62
14986930 2004

Variations for Oligodendroglioma

ClinVar genetic disease variations for Oligodendroglioma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CIC NM_001386298.1(CIC):c.3017_3018insT (p.Gly1008fs) INSERT Likely Pathogenic
635171 rs1568503055 GRCh37: 19:42791230-42791231
GRCh38: 19:42287078-42287079
2 ATRX NM_000489.6(ATRX):c.4213A>G (p.Arg1405Gly) SNV Uncertain Significance
635172 rs1569535987 GRCh37: X:76912051-76912051
GRCh38: X:77656561-77656561
3 IDH1 NM_005896.4(IDH1):c.395G>A (p.Arg132His) SNV Not Provided
156444 rs121913500 GRCh37: 2:209113112-209113112
GRCh38: 2:208248388-208248388

Cosmic variations for Oligodendroglioma:

8 (show top 50) (show all 19865)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263021 ZRSR2 central nervous system,brain,glioma,anaplastic c.260G>A p.R87K 23:15803744-15803744 6
2 COSM88262556 ZRSR2 central nervous system,brain,glioma,oligodendroglioma c.220G>A p.E74K 23:15803704-15803704 6
3 COSM102048054 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.-23-6501G>A p.? 16:72957466-72957466 6
4 COSM149299313 ZFHX3 central nervous system,brain,glioma,anaplastic c.145C>T p.P49S 16:72960001-72960001 6
5 COSM149332069 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.2680G>A p.D894N 16:72957466-72957466 6
6 COSM87281264 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.3986G>A p.G1329E 16:72798696-72798696 6
7 COSM149332063 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.9154G>A p.V3052I 16:72793528-72793528 6
8 COSM149268215 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.6025T>C p.Y2009H 16:72796657-72796657 6
9 COSM102034961 ZFHX3 central nervous system,brain,glioma,anaplastic c.-23-9036C>T p.? 16:72960001-72960001 6
10 COSM102019608 ZFHX3 central nervous system,brain,glioma,anaplastic c.5905A>G p.M1969V 16:72794035-72794035 6
11 COSM149261414 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8300G>A p.G2767E 16:72794382-72794382 6
12 COSM149260463 ZFHX3 central nervous system,brain,glioma,anaplastic c.8647A>G p.M2883V 16:72794035-72794035 6
13 COSM149318917 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8600C>T p.S2867F 16:72794082-72794082 6
14 COSM102020229 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.5558G>A p.G1853E 16:72794382-72794382 6
15 COSM87291808 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8600C>T p.S2867F 16:72794082-72794082 6
16 COSM87274123 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.6025T>C p.Y2009H 16:72796657-72796657 6
17 COSM102031113 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.1244G>A p.G415E 16:72798696-72798696 6
18 COSM87296761 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.9154G>A p.V3052I 16:72793528-72793528 6
19 COSM87271162 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.8300G>A p.G2767E 16:72794382-72794382 6
20 COSM102048046 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.6412G>A p.V2138I 16:72793528-72793528 6
21 COSM102022940 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.3283T>C p.Y1095H 16:72796657-72796657 6
22 COSM87284577 ZFHX3 central nervous system,brain,glioma,anaplastic c.145C>T p.P49S 16:72960001-72960001 6
23 COSM102042415 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.5858C>T p.S1953F 16:72794082-72794082 6
24 COSM87270740 ZFHX3 central nervous system,brain,glioma,anaplastic c.8647A>G p.M2883V 16:72794035-72794035 6
25 COSM149290610 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.3986G>A p.G1329E 16:72798696-72798696 6
26 COSM87296765 ZFHX3 central nervous system,brain,glioma,oligodendroglioma c.2680G>A p.D894N 16:72957466-72957466 6
27 COSM89896611 YES1 central nervous system,brain,glioma,oligodendroglioma c.259G>C p.A87P 18:756569-756569 6
28 COSM152022282 YES1 central nervous system,brain,glioma,oligodendroglioma c.259G>C p.A87P 18:756569-756569 6
29 COSM136838141 YES1 central nervous system,brain,glioma,oligodendroglioma c.274G>C p.A92P 18:756569-756569 6
30 COSM128446658 YAP1 central nervous system,brain,glioma,oligodendroglioma c.870+3470G>A p.? 11:102209544-102209544 6
31 COSM133267069 YAP1 central nervous system,brain,glioma,oligodendroglioma c.996+3458G>A p.? 11:102209544-102209544 6
32 COSM127992965 YAP1 central nervous system,brain,glioma,oligodendroglioma c.984+3470G>A p.? 11:102209544-102209544 6
33 COSM145022716 YAP1 central nervous system,brain,glioma,oligodendroglioma c.882+3458G>A p.? 11:102209544-102209544 6
34 COSM90942496 YAP1 central nervous system,brain,glioma,oligodendroglioma c.910G>A p.A304T 11:102209544-102209544 6
35 COSM143036045 YAP1 central nervous system,brain,glioma,oligodendroglioma c.1024G>A p.A342T 11:102209544-102209544 6
36 COSM126967812 YAP1 central nervous system,brain,glioma,oligodendroglioma c.478G>A p.A160T 11:102209544-102209544 6
37 COSM85231459 YAP1 central nervous system,brain,glioma,oligodendroglioma c.1012G>A p.A338T 11:102209544-102209544 6
38 COSM108084928 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 6
39 COSM94291565 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 6
40 COSM92181813 XIAP central nervous system,brain,glioma,anaplastic c.1057-2A>T p.? 23:123892729-123892729 6
41 COSM91365167 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 6
42 COSM149722178 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 6
43 COSM113469545 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 6
44 COSM148571772 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 6
45 COSM111523676 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 6
46 COSM147406409 WT1 central nervous system,brain,glioma,oligodendroglioma c.7G>A p.D3N 11:32435339-32435339 6
47 COSM95872527 VTCN1 central nervous system,brain,glioma,anaplastic c.413C>T p.S138F 1:117156615-117156615 6
48 COSM91946697 VTCN1 central nervous system,brain,glioma,anaplastic c.98-3246C>T p.? 1:117156615-117156615 6
49 COSM96870342 VTCN1 central nervous system,brain,glioma,anaplastic c.404C>T p.S135F 1:117156615-117156615 6
50 COSM108959161 VTCN1 central nervous system,brain,glioma,anaplastic c.*228C>T p.? 1:117156615-117156615 6

Copy number variations for Oligodendroglioma from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13342 1 1 124300000 Loss Oligodendroglial tumors
2 42816 10 40300000 135374737 Loss Oligodendroglial tumors
3 119741 18 16100000 76117153 Loss Oligodendroglial tumors
4 124095 19 1 28500000 Gain Oligodendroglial tumors
5 127178 19 28500000 63811651 Loss Oligodendroglial tumors
6 187538 4 50700000 191273063 Loss Oligodendroglial tumors
7 217108 7 1 59100000 Gain Oligodendroglial tumors
8 226562 7 59100000 158821424 Gain Oligodendroglial tumors
9 244959 9 1 51800000 Loss Oligodendroglial tumors

Expression for Oligodendroglioma

Search GEO for disease gene expression data for Oligodendroglioma.

Pathways for Oligodendroglioma

Pathways related to Oligodendroglioma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.34 TP53 PTEN MGMT EGFR CDKN2C CDKN2B
2
Show member pathways
12.61 TP53 POT1 CDKN2C CDKN2B CDKN2A
3
Show member pathways
12.59 TP53 PTEN EGFR CDKN2A BRAF
4
Show member pathways
12.37 GMNN CDKN2C CDKN2B CDKN2A
5
Show member pathways
12.34 TP53 PTEN EGFR BRAF
6
Show member pathways
12.12 TP53 CDKN2C CDKN2B CDKN2A
7
Show member pathways
12.11 TP53 PTEN EGFR BRAF
8 12.1 TP73 TP53 MGMT GMNN CDKN2C CDKN2A
9 12.02 BRAF EGFR PTEN TP53
10
Show member pathways
11.98 TP53 CDKN2C CDKN2B CDKN2A
11 11.95 TP53 PTEN EGFR BRAF
12 11.9 TP73 TP53 PTEN EGFR
13 11.84 TP53 MBP GFAP EGFR
14 11.82 TP73 TP53 PTEN
15
Show member pathways
11.8 TP73 TP53 CDKN2A
16 11.79 TP53 PTEN CDKN2B
17 11.78 TP53 PTEN CDKN2A BRAF
18 11.74 OLIG2 OLIG1 MBP GFAP
19 11.61 CDKN2A PTEN TP53
20 11.58 TP73 CDKN2C CDKN2A
21 11.57 SYP OLIG2 OLIG1 GFAP
22 11.49 TP53 PTEN EGFR CDKN2A
23 11.34 TP53 CDKN2C CDKN2B CDKN2A
24
Show member pathways
10.88 CDKN2A TP53 TP73
25 10.86 TP53 EGFR CDKN2A BRAF
26 10.61 TP53 BRAF
27 10.6 EGFR BRAF
28 10.44 TP53 CDKN2C CDKN2B CDKN2A

GO Terms for Oligodendroglioma

Biological processes related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 10.1 TP73 TP53 GMNN CDKN2C CDKN2B CDKN2A
2 negative regulation of cell population proliferation GO:0008285 10 CDKN2A CDKN2B CDKN2C PTEN TP53 TP73
3 isocitrate metabolic process GO:0006102 9.67 IDH2 IDH1
4 oligodendrocyte differentiation GO:0048709 9.62 OLIG2 OLIG1 CDKN2C
5 positive regulation of miRNA maturation GO:1903800 9.46 TP53 EGFR
6 glyoxylate cycle GO:0006097 9.46 IDH2 IDH1
7 regulation of axon regeneration GO:0048679 9.43 PTEN BRAF
8 negative regulation of phosphorylation GO:0042326 9.43 CDKN2C CDKN2B CDKN2A
9 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.23 PTEN CDKN2C CDKN2B CDKN2A

Molecular functions related to Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.93 TP73 TP53 PTEN CDKN2C CDKN2B CDKN2A
2 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.26 IDH2 IDH1
3 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.1 CDKN2C CDKN2B CDKN2A

Sources for Oligodendroglioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....